Clinical and histopathological characteristics of familial prostate cancer in Finland

BJU Int. 2012 Feb;109(4):557-63. doi: 10.1111/j.1464-410X.2011.10198.x. Epub 2011 Apr 20.

Abstract

Objective: • To describe clinical and histopathological characteristics of Finnish familial prostate cancer (PCa) through a detailed analysis of cases in families.

Patients and methods: • In total, 202 Finnish families with 617 histopathologically confirmed PCa cases of confirmed genealogy were collected. • Complete clinical data, including age and prostate-specific antigen (PSA) at diagnosis, stage, grade and primary treatment, were gathered. The mean (range) number of affected men per family was 3 (2-8). • All the available diagnostic biopsy samples (n= 323) were collected and regraded by the same uropathologist. • A population-based cohort of 3011 hospital district Pirkanmaa PCa patients was used as a control group.

Results: • The mean (range) year of diagnosis of PCa was 1993 (1962-2006) and the mean (range) age at diagnosis was 68 (43-98 years). • The median (range) primary PSA level was 12.0 (0.8-11 000) ng/mL. After regrading, the Gleason score was ≤6 in 38%, 7 in 37% and ≥8 in 25% of men. • The subset of familial PCa men diagnosed after 1995 had higher PSA levels (P= 9.9 × 10(-6) ) and an earlier age of onset (P= 1.7 × 10(-6) ) than men in the control group, although there were no differences in cancer-specific survival.

Conclusions: • We observed an earlier age of onset and higher PSA in familial PCa. • However, differences between sporadic and familial or hereditary PCa cannot be truly solved until genetic testing of high-risk genes in addition to family history is used to define PCa families. • We also emphasize that, when histological samples are collected over a longer study period, reanalysis of the samples by the same experienced uropathologist should be considered.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use
  • Case-Control Studies
  • Finland / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Orchiectomy / statistics & numerical data
  • Pedigree
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatectomy / statistics & numerical data
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy
  • Retrospective Studies
  • Survival Analysis

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen

Supplementary concepts

  • Prostate cancer, familial